Results 171 to 180 of about 2,002,433 (288)

Looking to the Future: Prospective Life Cycle Assessment of Emerging Technologies

Chemistry – A European Journal, EarlyView.
This review explores prospective life cycle assessment (pLCA), an emerging methodology for evaluating the environmental impacts of technologies still in development. Key aspects are identified, including assessing technology maturity levels, upscaling methods, and generating future scenarios.
Alessandro Marson, Alberto Benozzi, Alessandro Manzardo   +2 more
wiley   +1 more source

Formula Labelling in the United Kingdom: Manufacturers' Compliance With the Code, UK Law and Guidance Notes. [PDF]

Matern Child Nutr
Kamata M, Pereira-Kotze C, Kerac M, Sibson V.   +3 more
europepmc   +1 more source

Need for a Strong FOPL in India-position Statement. [PDF]

Indian J Community Med
Sharma N, Bahurupi Y, Garg S, Kapil U, Bhardwaj P, Bera OP, Singh M, Aggarwal P.   +7 more
europepmc   +1 more source

Impact of Regulatory Post‐Market Safety Advisories on Prescribing Practices: An Interrupted Time Series Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Less frequent adverse drug reactions are usually discovered after a drug's release to the market, making effective and timely communication of regulatory post‐market advisories essential for preventing emerging adverse effects. Time series analysis is a key study design for assessing the impact of post‐market safety advisories.
Seonji Kim, Subin Kim, Chungsoo Kim, Junhyuk Chang, Rae Woong Park, Kyung Won Kim, Seng Chan You   +6 more
wiley   +1 more source

Consumers' Health and Environmental Attitudes and Local Food Purchases. [PDF]

Int J Environ Res Public Health
Tran L, Su Y.
europepmc   +1 more source

A Benchmark, Expand, and Calibration (BenchExCal) Trial Emulation Approach for Using Real‐World Evidence to Support Indication Expansions: Design and Process for a Planned Empirical Evaluation

Clinical Pharmacology &Therapeutics, EarlyView.
Real‐world evidence involving healthcare database studies is well established for making causal inferences in post‐market drug safety studies and methods, data, and research infrastructure for evaluating effectiveness have advanced in recent years. The rapidly expanding field of etiologic research using insurance claims and electronic health records ...
Shirley V. Wang, Massimiliano Russo, Robert J. Glynn, Marie C. Bradley, Jiwei He, John Concato, Sebastian Schneeweiss   +6 more
wiley   +1 more source

Assessment of front and back of pack nutrition labels of selected convenience food products and snacks available in the Indian market. [PDF]

PLoS One
Shobana S, Sangavi G, Wuni R, Priyanka B, Leelavady A, Kayalvizhi D, Mohan Anjana R, Krishnaswamy K, Vimaleswaran KS, Mohan V.   +9 more
europepmc   +1 more source

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe, Timothy Nicholas, Gianluca Nucci, Cynthia J Musante, Brian Corrigan   +4 more
wiley   +1 more source

Mediating effect of dietary self-efficacy in the relationship between health literacy and nutrition label use among coronary heart disease patients. [PDF]

Sci Rep
Pan L, Xie C, Liu M, Zhu L.
europepmc   +1 more source

Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations

Clinical Pharmacology &Therapeutics, EarlyView.
A common issue in clinical drug development involves drug–drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population.
Alice S. Tang, Logan Brooks, Denise M. Boudreau, Pascal Chanu, Amita Joshi, Bianca Vora, Rui Zhu   +6 more
wiley   +1 more source